Pharming Group N.V./€PHARM
05:30
09:10
12:45
16:25
20:00
1D1W1MYTD1Y5YMAX
About Pharming Group N.V.
Pharming Group N.V. is a biotechnology company based in Leiden, Netherlands, focused on developing and commercializing innovative protein replacement therapies and precision medicines. The company's primary product, Ruconest, is an approved treatment for acute hereditary angioedema attacks, utilizing a recombinant form of the C1 esterase inhibitor. Established in 1988, Pharming leverages proprietary transgenic technology to produce human therapeutic proteins in the milk of genetically modified animals. With a strategic emphasis on rare diseases, the company aims to expand its pipeline through ongoing research and development activities. Pharming operates primarily in Europe and the United States, with partnerships and collaborations enhancing its global presence.
Ticker
€PHARM
Sector
Primary listing
AEX
Employees
407
Headquarters
Website
PHARM Metrics
BasicAdvanced
€619m
63.72
€0.01
0.12
-
Price and volume
Market cap
€619m
Beta
0.12
52-week high
€1.81
52-week low
€0.84
Average daily volume
9.2m
Financial strength
Current ratio
2.63
Quick ratio
2.049
Long term debt to equity
40.177
Total debt to equity
43.205
Interest coverage (TTM)
4.20%
Profitability
EBITDA (TTM)
36.738
Gross margin (TTM)
88.14%
Net profit margin (TTM)
3.34%
Operating margin (TTM)
9.44%
Effective tax rate (TTM)
38.57%
Revenue per employee (TTM)
€790,680
Management effectiveness
Return on assets (TTM)
4.89%
Return on equity (TTM)
5.04%
Valuation
Price to earnings (TTM)
63.725
Price to revenue (TTM)
1.991
Price to book
2.42
Price to tangible book (TTM)
4.73
Price to free cash flow (TTM)
13.203
Free cash flow yield (TTM)
7.57%
Free cash flow per share (TTM)
0.068
Growth
Revenue change (TTM)
15.21%
Earnings per share change (TTM)
-176.69%
3-year revenue growth (CAGR)
22.39%
10-year revenue growth (CAGR)
39.77%
3-year earnings per share growth (CAGR)
66.89%
10-year earnings per share growth (CAGR)
-7.16%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.